Despite Recent Gains, Lyra Therapeutics Insiders Are Still Down US66k
LYRA Stock | USD 0.18 0.00 0.000006% |
About 55% of Lyra Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Lyra Therapeutics suggests that some traders are interested. The current market sentiment, together with Lyra Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lyra Therapeutics stock news signals to limit their universe of possible portfolio assets.
Lyra |
Insiders who purchased US74.1k worth of Lyra Therapeutics, Inc. shares over the past year recouped...
Read at simplywall.st
Lyra Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Lyra Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Lyra Therapeutics Fundamental Analysis
We analyze Lyra Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lyra Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lyra Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Lyra Therapeutics is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Lyra Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lyra Therapeutics stock to make a market-neutral strategy. Peer analysis of Lyra Therapeutics could also be used in its relative valuation, which is a method of valuing Lyra Therapeutics by comparing valuation metrics with similar companies.
Peers
Lyra Therapeutics Related Equities
CGEM | Cullinan Oncology | 5.94 | ||||
DAWN | Day One | 2.65 | ||||
TIL | Instil Bio | 2.64 | ||||
AUTL | Autolus Therapeutics | 2.23 | ||||
ACHL | Achilles Therapeutics | 1.03 | ||||
NXTC | NextCure | 0 | ||||
NUVB | Nuvation Bio | 0.37 | ||||
CTMX | CytomX Therapeutics | 0.91 | ||||
ASMB | Assembly Biosciences | 3.80 | ||||
SPRO | Spero Therapeutics | 4.00 | ||||
BOLT | Bolt Biotherapeutics | 7.41 |
Complementary Tools for Lyra Stock analysis
When running Lyra Therapeutics' price analysis, check to measure Lyra Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lyra Therapeutics is operating at the current time. Most of Lyra Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lyra Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lyra Therapeutics' price. Additionally, you may evaluate how the addition of Lyra Therapeutics to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |